Patents Issued in March 13, 2018
  • Patent number: 9913887
    Abstract: The present invention encompasses methods and compositions for Ureaplasma infection prevention and/or treatment. In specific cases, the invention concerns vaccines for Ureaplasma, including DNA vaccines. In certain embodiments, the invention regards vaccines directed towards the multiple-banded antigen(s) of Ureaplasma.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 13, 2018
    Assignee: Baylor College of Medicine
    Inventors: Leonard Weisman, Lingkun Kong
  • Patent number: 9913888
    Abstract: The present document discloses a new species of Bizionia, herein denoted Bizionia piscinecroseptica and a reference strain of this bacterium denoted Bizionia sp. 130524K2F7 which has been deposited at the National Collection of Industrial and Marine Bacteria and has been assigned accession number NCIMB 42183. Further disclosed is the medical use of bacteria of the genus Bizionia for vaccinating fish against a new disease identified and herein denoted bizioniosis.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 13, 2018
    Assignee: NORGES MILJØ- OG BIOVITENSKAPELIGE UNIVERSITET (NMBU)
    Inventor: Henning Sørum
  • Patent number: 9913889
    Abstract: The present application provides methods of stimulating an immune response, such as a protective immune response against Treponema pallidum infection. Such methods utilize fragments of the Tp0751 protein (such as any of SEQ ID NOs: 3-10, those N-terminally truncated from amino acids 1 through 77, 1 through 114, or anywhere in between, e.g., those that start at any amino acid from 78 to 115). In some examples, a Tp0751 protein fragment has a mutated HEXXH site (HEXXH is the wild-type sequence). Also provided are the isolated soluble Tp0751 protein fragments that include a wild-type or mutated HEXXH site, as well as nucleic acids encoding such proteins and kits that include such proteins.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: March 13, 2018
    Assignee: UVic Industry Partnerships Inc.
    Inventors: Caroline E. Cameron, Rebecca M. Hof, Simon A. Houston, Martin John Boulanger
  • Patent number: 9913890
    Abstract: Compositions effective for treating or preventing an anthrax infection in a subject in need thereof and recombinant proteins included in the compositions are provided. Methods for producing recombinant proteins in plants are described. Transgenic plants engineered to produce recombinant proteins as well as genetic constructs comprising nucleic acids encoding recombinant proteins thereof are also described. Methods of protecting subjects against anthrax infection with plant-derived compositions are provided.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: March 13, 2018
    Assignee: PHARMA GREEN LLC
    Inventors: Vyacheslav Andrianov, Maxim Golovkin
  • Patent number: 9913891
    Abstract: The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV. The invention further encompasses methods of making or producing antigenic polypeptides or antigens.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: March 13, 2018
    Assignee: MERIAL INC.
    Inventors: Jean-Christophe Audonnet, Frédéric Reynard, Natalia Bomchil, Cécile Sigoillot-Claude
  • Patent number: 9913892
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC., CORNELL RESEARCH FOUNDATION, INC., THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 9913893
    Abstract: Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: March 13, 2018
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Luc Berghman, Walter Bottje, Billy Hargis, Sherryll Layton
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Patent number: 9913895
    Abstract: The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and SIV, or between HIV and FIV. In another embodiment, the epitope is one that is conserved between HIV, SIV, and FIV.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: March 13, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Janet K. Yamamoto
  • Patent number: 9913896
    Abstract: This disclosure provides an attenuated palmiped parvovirus that affords heterologous protection for both Muscovy duck parvovirus and goose parvovirus (i.e., Derzsy's Disease). The disclosure further provides compositions comprising the same, and methods of production and use thereof.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: March 13, 2018
    Assignee: MERIAL, INC.
    Inventor: Francois Xavier Le Gros
  • Patent number: 9913898
    Abstract: The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: March 13, 2018
    Assignee: Valneva Austria GmbH
    Inventors: Robert Schlegl, Michael Möhlen, Jürgen Wruss, Michael Weber
  • Patent number: 9913899
    Abstract: Identification of candidates for treatment and treatment of subjects experiencing cerebral ischemia wherein the treatment employs a thrombolytic or thrombectomy agent and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are determined by testing the blood of a patient for total S-100B or for S-100BB as a marker of blood brain barrier integrity.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: March 13, 2018
    Assignee: Shimojani, LLC
    Inventors: Lawrence M. Kauvar, Damir Janigro
  • Patent number: 9913900
    Abstract: The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 13, 2018
    Assignees: AMGEN INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Hua Zhu Ke, Min Liu, William V. Giannobile
  • Patent number: 9913901
    Abstract: Methods for treating cancer patients with HER2-positive tumors are disclosed. The methods comprise administering to a patient a therapeutically effective amount of a combination of (i) an anthracycline-loaded immunoliposome with a targeting moiety that is a first anti-HER2 antibody and (ii) an anti-cancer therapeutic comprising a second anti-HER2 antibody.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 13, 2018
    Assignee: Merrimack Pharmaceuticals, Inc.
    Inventors: Victor Moyo, Bart S. Hendriks, Thomas Wickham, Elena Geretti, Joseph G. Reynolds, Christopher W. Espelin
  • Patent number: 9913902
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 13, 2018
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Patent number: 9913903
    Abstract: Embodiments of the present invention provide methods for the treatment or prevention of infection-related immune conditions using compositions comprising IgM.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: March 13, 2018
    Assignee: Grifols Worldwide Operations Limited
    Inventors: Thomas Barnett, David A. Ross
  • Patent number: 9913904
    Abstract: The present invention relates to the use of a composition selected from the group consisting of antibodies, antibody fragments, insulin-like growth factor antagonists, Toll-like receptor antagonists and mixtures thereof for the treatment or the prophylaxis of certain diseases.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: March 13, 2018
    Assignee: IGNOVA GMBH
    Inventors: Jan Wesjohann, Günter Sprotte, Ana Maria Waaga-Gasser
  • Patent number: 9913905
    Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous (SC) or intramuscular (IM) injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and organophosphates. The viscosity of the formulation is significantly reduced by the addition of one or more organophosphates.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: March 13, 2018
    Assignee: EAGLE BIOLOGICS, INC.
    Inventors: Alyssa M. Larson, Alisha K. Weight, Kevin Love, Alan Crane, Robert S. Langer, Alexander M. Klibanov
  • Patent number: 9913906
    Abstract: An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: March 13, 2018
    Inventor: Karen K. Brown
  • Patent number: 9913907
    Abstract: The present invention provides a composition for suppressing the expression of a KRAS gene, comprising a lipid particle containing, as a drug, a double-stranded nucleic acid having an antisense strand having a sequence of bases complementary to the sequence of at least 19 continuous bases of any one KRAS gene's mRNA of sequence Nos. 1 to 3; and a cationic lipid represented by the following formula (I): wherein R1 and R2, which are the same or different, are each linear or branched alkyl, alkenyl or alkynyl having a carbon number of from 12 to 24; L1 and L2, which are the same or different, are each —CO—O— or —O—CO—; a and b, which are the same or different, are each 1 to 3; and R3 is a hydrogen atom, alkyl having a carbon number of from 1 to 6, or alkenyl having a carbon number of from 3 to 6, and the like.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: March 13, 2018
    Assignees: KYOWA HAKKO KIRIN CO., LTD., DICERNA PHARMACEUTICALS, INC.
    Inventors: Tomoyuki Naoi, Takeshi Kuboyama, Junichi Enokizono, Toshihiko Ishii, Akihiro Tokunaga, Kentarou Hatanaka
  • Patent number: 9913908
    Abstract: The present disclosure refers to transdermal pharmaceutical bases that include a synergistic combination of a silicone base with a natural permeation enhancement composition (NPE). Further, these transdermal pharmaceutical bases are proposed to treat ear diseases in mammals. The silicone base includes silicone, pracaxi oil, and seje oil. Additionally, the NPE composition includes one or more phospholipids, one or more oils rich in essential fatty acids, behenic acid, and oleic acid, one or more skin lipids, and one or more butters rich in linoleic acid and linolenic acid. The synergistic combination of aforementioned natural components exhibit enhanced healing properties, thereby providing organic acids with antioxidant, antibacterial, and antifungal properties. The transdermal pharmaceutical bases are employed to increase the residence time of the medicament in the ear canal, and increase the penetration of the APIs into the affected area, thereby enhancing treatment effectiveness.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 13, 2018
    Assignee: Professional Compounding Centers of America
    Inventors: Chris V. Simmons, Daniel Banov
  • Patent number: 9913909
    Abstract: Delivery systems and compositions comprised of a biodegradable polyorthoester polymer, an aprotic solvent, and a drug are described. The solvent is selected to modulate release of drug from the composition, where, in some embodiments, the solvent is rapidly released after administration and provides a corresponding rapid rate of drug release. Alternatively, in other embodiments, the solvent is slowly released from the composition after its administration, and provides a correspondingly slow rate of drug release.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 13, 2018
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Lee Ann Lynn Schillinger
  • Patent number: 9913910
    Abstract: A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: March 13, 2018
    Assignee: Heron Therapeutics, Inc.
    Inventors: Steven Y. Ng, Hui-Rong Shen, Jorge Heller
  • Patent number: 9913911
    Abstract: Carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid and a linkage cleavable under reducing conditions, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle and related compositions, methods and systems.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: March 13, 2018
    Assignee: California Institute of Technology
    Inventors: Mark E. Davis, Akinleye Alabi
  • Patent number: 9913912
    Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: March 13, 2018
    Assignee: Ascendis Pharma A/S
    Inventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge
  • Patent number: 9913913
    Abstract: A method for preparing a polymeric reagent is provided, which method includes the optional step of forming an N-hydroxysuccinimdyl ester derivative. Related methods, preparations, and so forth are also provided.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 13, 2018
    Assignee: Nektar Therapeutics
    Inventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
  • Patent number: 9913914
    Abstract: The invention relates to novel polypeptides for transporting molecules across cell membranes and, particularly but not exclusively, biological membranes; a conjugate comprising at least one of said polypeptides and at least one selected molecule or agent co-joined or conjugated to said polypeptide for the purpose of transporting said molecule or agent across a cell membrane; a method of transporting at least one selected molecule or agent across a cell membrane involving the use of at least one of said polypeptides; a therapeutic comprising at least one of said conjugates; a combination therapeutic comprising at least one of said conjugates and at least one further therapeutic agent; a method of treatment involving the use of at least one of said conjugates or said therapeutics.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: March 13, 2018
    Assignee: CUPID PEPTIDE COMPANY LIMITED
    Inventor: William Jonathan Ryves
  • Patent number: 9913915
    Abstract: Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 13, 2018
    Assignee: Ophidion Inc.
    Inventor: Andreas Walz
  • Patent number: 9913916
    Abstract: Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: March 13, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Joseph M. DeSimone, Mathew Finniss, Mary Napier, Ashish Pandya, Matthew Parrott
  • Patent number: 9913917
    Abstract: The invention relates to highly fluorescent metal oxide nanoparticles to which biomolecules and other compounds can be chemically linked to form biocompatible, stable optical imaging agents for in vitro and in vivo applications. The fluorescent metal oxide nanoparticles may also be used for magnetic resonance imaging (MRI), thus providing a multi modality imaging agent.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: March 13, 2018
    Assignee: VisEn Medical, Inc.
    Inventors: Kevin Groves, Milind Rajopadhye
  • Patent number: 9913918
    Abstract: Recombinant host cells are provided. The cell genome contains heterologous gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamAB operon, the mamGDFC operon, and the tmms6 operon of a magnetotactic alphaproteobacterium, respectively. The cells may further comprise gene expression cassettes capable of being expressed in the host cell, where the gene expression cassettes encode a nucleic acid sequence encompassing at least 80% of the full-length sequence of the mamXY operon and/or the feoABI operon of a magnetotactic alphaproteobacterium; where the recombinant host cell, upon expression of the gene expression cassettes in their entirety, is capable of producing magnetic nanoparticles. Preferably, the recombinant host cell is derived from Rhodospirillum rubrum. Methods of producing these recombinant host cells by genetic transposition are provided.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: March 13, 2018
    Assignee: UNIVERSITAT BAYREUTH
    Inventors: Dirk Schüler, Isabel Kolinko
  • Patent number: 9913919
    Abstract: Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: March 13, 2018
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Simon P. Robinson, Robert W. Siegler, Nhung Tuyet Nguyen, David C. Onthank, Tarakeshwar Vishwanath Anklekar, Charles Chester Van Kirk
  • Patent number: 9913920
    Abstract: The disclosure relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: March 13, 2018
    Assignees: VIB VZW, Vrije Universiteit Brussel
    Inventors: Kiavash Movahedi, Damya Laoui, Steve Schoonooghe, Geert Raes, Patrick De Baetselier, Jo Van Ginderachter, Nick Devoogdt, Tony Lahoutte
  • Patent number: 9913921
    Abstract: Described is a pretargeting method, and related kits, for targeted medical imaging and/or therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention involves the use of [4+2] inverse electron demand (retro) Diels-Alder chemistry in providing the coupling between a Pre-targeting Probe and an Effector Probe. To this end one of these probes comprises an electron-deficient tetrazine or other suitable diene, and the other an E-cyclooctene which has a flattened structure as a result of the position of at least two exocyclic bonds.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: March 13, 2018
    Assignee: TAGWORKS PHARMACEUTICALS B.V.
    Inventors: Marc Stefan Robillard, Johan Lub, Raffaella Rossin, Sandra Martina Van Ben Bosch, Ronny Mathieu Versteegen
  • Patent number: 9913922
    Abstract: A sterilizing component removal device which reduces a sterilizing component sprayed in a working chamber having an outlet includes a sprayer which supplies, in an atomized manner, a liquid different from the sterilizing component into the working chamber.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: March 13, 2018
    Assignees: PANASONIC CORPORATION, Panasonic Healthcare Co., Ltd.
    Inventors: Hiroko Murayama, Tatsushi Ohyama, Masahiro Iseki, Hironobu Sekine, Koichi Kobayashi, Hiroshi Yamamoto
  • Patent number: 9913923
    Abstract: A system for decontaminating an enclosed area includes a reservoir containing a disinfectant solution therein. One or more pumps are in fluid communication with the reservoir. One or more ports are operatively connected to the reservoir or operatively connected to an enclosed area to be decontaminated or operatively connected to the reservoir and to an enclosed area to be decontaminated. One or more connector assemblies are removably attachable to the one or more ports to provide fluid flow communication between the disinfectant solution source and the enclosure to be decontaminated.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: March 13, 2018
    Assignee: Aeroclave, LLC
    Inventors: Ronald D. Brown, David J. Robinson, James S. Amrhein
  • Patent number: 9913924
    Abstract: A dispensing device for release of a volatile material includes a base, a drive arm coupled to a pendulum based drive mechanism, and a refill coupled to the drive arm. The refill includes a support base, at least one flange, a substrate coupled with the at least one flange, and a use-up cue.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: March 13, 2018
    Assignee: S. C. Johnson & Son, Inc.
    Inventors: Joel E. Adair, Brian T. Davis, Gregory A. Falduto, Michelle Dekea Fason, Kamran Faterioun, Donald J. Schumacher, Paulina Carlos Trevino, Katlyn Ross, Shawn Smith, Evan A. Sparks
  • Patent number: 9913925
    Abstract: Nonwoven (and film) topsheet and acquisition/distribution materials treated with a hydrophilic, synthetic surfactant-free finish, absorbent articles for infant or incontinence care that contain these materials, and methods for apply such finishes and/or making such absorbent articles.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 13, 2018
    Assignee: ATTENDS HEALTHCARE PRODUCTS, INC.
    Inventor: Harry J. Chmielewski
  • Patent number: 9913926
    Abstract: Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 13, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Russell J. Stewart, Hui Shao
  • Patent number: 9913927
    Abstract: Described herein are fluid complex coacervates that produce solid adhesives in situ. Oppositely charged polyelectrolytes were designed to form fluid adhesive complex coacervates at ionic strengths higher than the ionic strength of the application site, but an insoluble adhesive solid or gel at the application site. When the fluid, high ionic strength adhesive complex coacervates are introduced into the lower ionic strength application site, the fluid complex coacervate is converted to a an adhesive solid or gel as the salt concentration in the complex coacervate equilibrates to the application site salt concentration. In one embodiment, the fluid complex coacervates are designed to solidify in situ at physiological ionic strength and have numerous medical applications. In other aspects, the fluid complex coacervates can be used in aqueous environment for non-medical applications.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: March 13, 2018
    Assignee: University of Utah Research Foundation
    Inventor: Russell J. Stewart
  • Patent number: 9913928
    Abstract: The present invention relates to a macroporous, resorbable and injectable apatitic calcium-phosphate cement with a high compressive strength useful as bone cement and releasing a bone resorption inhibitor, preparation method and uses thereof.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 13, 2018
    Assignees: GRAFTYS, UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
    Inventors: Jean-Michel Bouler, Bruno Bujoli, Pascal Janvier, Ibrahim Khairoun, Jean-Noël Argenson
  • Patent number: 9913929
    Abstract: A method of preparing a bone graft. Mixing bone marrow aspirate with an effective amount of a binding reagent that is capable of binding with red blood cells in the bone marrow aspirate. The bound red blood cells are aggregated. The aggregated bound red blood cells are separated from the bone marrow aspirate to provide a supernatant. At least a portion of the supernatant is associated with an osteoconductive matrix to form the bone graft.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: March 13, 2018
    Assignee: Fortus Medical, Inc.
    Inventor: Robert Assell
  • Patent number: 9913930
    Abstract: Described herein are methods for implanting cells into a host comprising the steps of implanting into the host a device comprising a cell encapsulation chamber with at least one seal, allowing the device to vascularize, and loading the device with a human embryonic stem (hES) cell-derived pancreatic progenitor cell population.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 13, 2018
    Assignee: VIACYTE, INC.
    Inventors: Laura Martinson, Chad Green, Evert Kroon, Emmanuel Edward Baetge
  • Patent number: 9913931
    Abstract: A calcium phosphate monetite cement-forming composition comprises a monetite-forming calcium-based precursor powder and from 3 to 30 wt %, based on the weight of the precursor powder, of dicalcium pyrophosphate powder. Monetite cements formed form such compositions may be used in implants for correcting bone defects. Methods for bone defect repair employ implants formed from such monetite cements and slow implant resorption and/or improve in vivo bone induction in a patient.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 13, 2018
    Assignee: OSSDSIGN AB
    Inventors: Jonas Åberg, Thomas Engstrand, Håkan Engqvist
  • Patent number: 9913932
    Abstract: The present invention relates to methods for providing polymeric composites with bone forming, such as with osteogenic and/or osteoinductive and/or osteoconductive, properties. The present invention further relates to polymeric composites provided by the present method and the use of thereof for bone implants, or grafts, specifically the use thereof for orbital floor reconstruction. Specifically, the present invention relates to methods for providing a composite with bone forming properties, the method comprises the steps of: a) providing a liquid, or liquefied, polymeric composition of homopolymers or copolymers of 1,3-trimethylene carbonate (TMC); b) adding to said liquid, or liquefied, polymeric composition one or more agents with osteogenic and/or osteoinductive and/or osteoconductive properties thereby providing a dispersion of said agents in said liquid or liquefied polymeric composition; and c) crosslinking the product obtained, thereby providing a composite with bone forming properties.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: March 13, 2018
    Assignees: UNIVERSITEIT TWENTE, RUKSUNIVERSITEIT GRONINGEN, ACADEMISCH ZIEKENHUIS GRONINGEN
    Inventors: Dirk Wybe Grijpma, Rudolf Robert Maria Bos, Anne Cornelis Van Leeuwen
  • Patent number: 9913933
    Abstract: In various embodiments of the present disclosure, a surgical catheter is provided. The present disclosure provides a catheter shaft that includes a distal portion and a proximal portion. The proximal portion comprises a handle operably connected to the distal portion of the elongated structure. The distal portion three radially positioned polymeric layers. At least two of the layers include chemically dissimilar polymers and at least one of the three layers includes functionalized polyvinylidene fluoride (PVDF).
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 13, 2018
    Assignee: St. Jude Medical, Cardiology Division, Inc.
    Inventors: Xiaoping Guo, David P. Johnson
  • Patent number: 9913934
    Abstract: A radiopaque, optically translucent thermoplastic polyurethane compound is disclosed. The use of nano-sized particles of barium sulfate optionally in combination with a minor amount of certain dispersion aids allows the barium sulfate to be sufficiently dispersed within the thermoplastic polyurethane to retain optical translucency according to a defined Haze Determination Test. Medical devices, needing both visual spectrum observation before and during in-vivo medical use and radiopacity monitoring during in-vivo medical use, benefit from this compound. Optionally, a surface enhancer can also be used.
    Type: Grant
    Filed: September 8, 2014
    Date of Patent: March 13, 2018
    Assignee: PolyOne Corporation
    Inventors: Jack Frautschi, Jing Liu, Jiannong Xu
  • Patent number: 9913935
    Abstract: A catheter connector assembly which may be included with a corporeal drainage system, and a method of draining fluid from a bodily cavity. The catheter connector assembly may include a catheter connector and a drainage line connector. The catheter connector may include a connector body with a coupling feature, a deformable sealing element, and a retaining member. The drainage line connector may include a drainage line body first and second hinge clips, and an actuator. The actuator is designed to deform the deformable sealing element when the drainage line connector is coupled to the catheter connector.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: March 13, 2018
    Assignee: C. R. Bard, Inc.
    Inventors: Mark A. Christensen, Steven M. Smith, Jim C. Beasley, Kelly B. Powers
  • Patent number: 9913936
    Abstract: A method for aspirating material from a patient includes providing an elongate tubular member having a lumen having a first diameter adjacent its distal end, providing an aspiration catheter including a tubular aspiration member having an aspiration lumen and configured to at least partially extend out of the lumen of the elongate tubular member, an elongate support member coupled to the tubular aspiration member, and at least one annular sealing member coupled to the tubular aspiration member and configured to seal against the first diameter, placing the distal end of the elongate tubular member into vasculature, inserting the aspiration catheter into the lumen of the elongate tubular member, extending the distal end of the tubular aspiration member out of the distal end of the elongate tubular member such that the at least one annular sealing member is aligned with the first diameter of the lumen of the elongate tubular member, and applying a vacuum to the lumen of the elongate tubular member at the such th
    Type: Grant
    Filed: July 14, 2016
    Date of Patent: March 13, 2018
    Assignee: INCUVATE, LLC
    Inventors: David M. Look, Bradley S. Culbert
  • Patent number: 9913937
    Abstract: Apparatus and methods are described including identifying a subject as suffering from a condition selected from the group consisting of: cardiac dysfunction, congestive heart failure, reduced renal blood flow, increased renal vascular resistance, arterial hypertension, and kidney dysfunction. In response thereto, blood pressure within a renal vein of the subject is reduced, by placing a blood pump inside the subject's renal vein and activating the impeller to pump blood from the renal vein into the subject's vena cava. Other applications are also described.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: March 13, 2018
    Assignee: MAGENTA MEDICAL LTD.
    Inventors: Ehud Schwammenthal, Yosi Tuval, Daniel Glozman